M.D. Anderson Cancer Center: Ovarian Neoplasms trials

The registry lists 68 Ovarian Neoplasms studies with M.D. Anderson Cancer Center as lead sponsor. 15 are open to participants now and 13 have results posted.

Early Phase 1 3Phase 1 23Phase 2 22Phase 3 1No phase 22(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian CancerRecruitingNCT06545604Not applicable
• Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline TherapyRecruitingNCT06083844Phase 2
• Spanish Decision Tool for Ovarian Cancer Maintenance TherapyRecruitingNCT06036810Not applicable
• Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.RecruitingNCT05649072Not applicable
• Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian CancerRecruitingNCT05636111Phase 1
• Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort StudyRecruitingNCT05287451Not applicable
• Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)RecruitingNCT05123807Phase 2
• Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxRecruitingNCT05092373Phase 1
• IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsRecruitingNCT05039801Phase 1
• Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE TrialRecruitingNCT04575935Phase 3
• Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer PatientsRecruitingNCT04038619Phase 1
• Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic CancersRecruitingNCT03968406Phase 1
• Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTFRecruitingNCT03604315Phase 1
• Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk WomenRecruitingNCT00539162Not applicable
• Data Collection for Patients With Low Grade Ovarian or Peritoneal TumorsRecruitingNCT00488878
• EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian CancerActive, not recruitingNCT05715216Phase 2Results posted
• Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN AlterationsTerminatedNCT05082025Phase 2Results posted
• Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE StudyTerminatedNCT04066894Phase 2Results posted
• AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT04019288Phase 1/2Results posted
• Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal AdenocarcinomaTerminatedNCT03610490Phase 2Results posted
• Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03026062Phase 2Results posted
• First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube CancerCompletedNCT01097746Phase 2Results posted
• Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer PatientsTerminatedNCT00583622Phase 2Results posted
• Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid TumorTerminatedNCT00523809Phase 2Results posted
• Gleevec Study for Patients With Ovarian CancerCompletedNCT00510653Phase 2Results posted
• Letrozole in Patients With Ovarian TumorsTerminatedNCT00505661Phase 2Results posted
• Chemoimmunotherapy Study for Patients With Epithelial Ovarian CancerCompletedNCT00501644Phase 2Results posted
• Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00317772Phase 1/2Results posted
• Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic CancerActive, not recruitingNCT05922930Phase 1/2
• Early Assessment of Ovarian Cancer Aggressiveness by Metabolic ImagingSuspendedNCT05866679Phase 1
• Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) InterventionActive, not recruitingNCT05677048Not applicable
• Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid TumorsActive, not recruitingNCT05075993Phase 1
• Infertility Survey Among Reproductive Age Women With Gynecological and Breast CancerActive, not recruitingNCT04678414
• Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin ChemotherapyActive, not recruitingNCT04310826Not applicable
• Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their RelativesCompletedNCT04257045
• PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian CancerActive, not recruitingNCT03965481Not applicable
• Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before SurgeryActive, not recruitingNCT03943173Early Phase 1
• A Phase I Study of SOR-C13 in Patients With Advanced Solid TumorsCompletedNCT03784677Phase 1
• TAK-659 and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT03756818Phase 1
• Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03586661Phase 1
• Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT03579316Phase 2
• Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisCompletedNCT03508570Phase 1
• LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasActive, not recruitingNCT03449108Phase 2
• Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look SurgeryActive, not recruitingNCT02884648Phase 2
• Mesenchymal Stem Cells (MSC) for Ovarian CancerCompletedNCT02530047Phase 1
• Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02316834Early Phase 1
• mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianActive, not recruitingNCT02208375Phase 1
• Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family MembersActive, not recruitingNCT02194387Not applicable
• Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian CancerActive, not recruitingNCT02043158
• Prophylactic Salpingectomy With Delayed OophorectomyActive, not recruitingNCT01907789Not applicable
• Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01504126Early Phase 1
• Juice Plus+ and Juice Plus+ Complete in Ovarian CancerActive, not recruitingNCT01439659Phase 2
• M. D. Anderson Symptom Inventory - Ovarian CancerCompletedNCT01037751
• Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)CompletedNCT00829959
• Topical Cyclosporine vs. Placebo for Epiphora Associated With DocetaxelWithdrawnNCT00824811Phase 2
• Cost Utility Analysis in Recurrent Ovarian CancerWithdrawnNCT00813254
• Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal CancerWithdrawnNCT00634894Phase 2
• Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian CancerCompletedNCT00529022Phase 1
• Depression Treatment and Screening in Ovarian Cancer PatientsActive, not recruitingNCT00515372Phase 1
• Quality of Life Associated With a Low-Risk Screening Program for Ovarian CancerStatus unknownNCT00511641
• Chemotherapy-Related Toxicities In Ovarian Cancer PatientsCompletedNCT00508378
• Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube CancerStatus unknownNCT00499512
• Ovarian Cancer Patient Questionnaire on Genetic TestingCompletedNCT00486707
• Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal CancerCompletedNCT00436657Phase 1
• Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian CancerCompletedNCT00431054Phase 1
• Elizabeth Registry for Low Grade Ovarian CancerCompletedNCT00345709
• Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian CancerTerminatedNCT00102622Phase 1
• PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube CancerCompletedNCT00059618Phase 1